文献速递肝病消化道肿瘤与早癌消化内镜

美国肝硬化患者监测现状仍不理想

Surveillance of patients with cirrhosis remains suboptimal in the United States.
PubMed 文献 · J Hepatol · 2021-05-07

该研究基于2007-2016年美国Truven Health MarketScan数据库82,427例肝硬化患者,评估实验室监测、肝细胞癌(HCC)和食管静脉曲张(EV)监测的频率及相关因素。结果显示HCC监测(8.78%)、每6-12个月实验室检测(29.72%)和每1-2年EV监测(10.6%)的比例均不理想,多数患者整个研究期间未接受HCC(45.4%)或EV(80.3%)监测。

要点

  • 肝硬化患者HCC监测率仅8.78%,EV监测率仅10.6%,均远低于推荐要求。
  • 仅29.72%患者至少每6-12个月进行实验室检测,多数未规律监测。
  • 专科护理、失代偿期肝硬化及NAFLD等因素与更高的监测几率相关。

核心结论

  • 尽管近年略有改善,美国肝硬化患者的常规监测和筛查仍不理想,亟需通过提高医生意识、患者教育和系统激励等措施改进。

研究设计与样本

  • 基于Truven Health MarketScan Research Database 2007-2016年数据,纳入82,427例肝硬化患者(43,280例代偿期,39,147例失代偿期),计算各项监测频率并采用多因素logistic回归分析相关因素。

主要发现

  • 接受HCC监测的患者比例为8.78%,至少每6-12个月进行实验室检测的比例为29.72%,至少每1-2年进行EV监测的比例为10.6%。
  • 整个研究期间,45.4%的患者未接受HCC监测,80.3%的患者未接受EV监测。
  • 年龄41-55岁(对比<41岁)、优选提供者组织保险计划(对比健康维护组织)、专科护理(对比初级保健及其他专科)、2013-2016年诊断(对比2007-2009年)、失代偿期肝硬化(对比代偿期)、非酒精性脂肪性肝病(对比病毒性肝炎)及更高的Charlson合并症指数与每6-12个月检测和每1-2年EV监测的更高几率显著相关。

临床怎么用

  • 消化内科医生应提高对肝硬化患者常规监测的认识,尤其关注初级保健和非专科管理的患者。
  • 针对HCC和EV监测率低的现状,应加强患者教育并推动系统层面的质量改进措施。

局限性

  • 研究基于行政索赔数据库,可能受编码准确性影响;未报告监测依从性的具体原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Regular monitoring/surveillance for liver complications is crucial to reduce morbidity and mortality in patients with cirrhosis. Recommendations from professional societies are available but adherence is not well studied, especially outside of academic centers. We aimed to determine the frequencies and factors associated with laboratory monitoring, and hepatocellular carcinoma (HCC) and esophageal varices (EV) surveillance in patients with cirrhosis. METHODS: We identified 82,427 patients with cirrhosis (43,280 compensated and 39,147 decompensated) from the Truven Health MarketScan Research Database®, 2007-2016. We calculated the proportion of patients with cirrhosis with various frequencies of procedures/testing: laboratory (complete blood count, comprehensive metabolic panel, and prothrombin time), HCC and EV surveillance. We also used multivariable logistic regression to determine factors associated with having procedures. RESULTS: The proportions of patients undergoing HCC surveillance (8.78%), laboratory testing (29.72%) at least every 6-12 months, or EV surveillance (10.6%) at least every 1-2 years were suboptimal. The majority did not have HCC (45.4%) or EV (80.3%) surveillance during the entire study period. On multivariable regression, age 41-55 (vs. <41) years, preferred provider organization (vs. health maintenance organization) insurance plan, specialist care (vs. primary care and other specialties), diagnosis between 2013-2016 (vs. 2007-2009), decompensated (vs. compensated) cirrhosis, non-alcoholic fatty liver disease (vs. viral hepatitis), and higher Charlson comorbidity index were associated with significantly higher odds of undergoing procedures/testing every 6-12 months and EV surveillance every 1-2 years. CONCLUSIONS: Despite modest improvements in more recent years, routine monitoring and surveillance for patients with cirrhosis is suboptimal. Further efforts including provider awareness, patient education, and system/incentive-based quality improvement measures are urgently needed. LAY SUMMARY: Patients with cirrhosis should undergo health monitoring for liver complications to achieve early detection and treatment. In a large nationwide cohort of 82,427 patients with cirrhosis in the United States, we found a low rate of adherence (well less than half) to routine blood test monitoring and surveillance for liver cancer and esophageal varices (swollen blood vessels in the abdomen that could lead to fatal bleeding). Adherence has increased in the recent years, but much more improvement is needed.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yeo YH, Hwang J, Jeong D, et al. Surveillance of patients with cirrhosis remains suboptimal in the United States. J Hepatol. 2021. PMID: 33965477. doi:10.1016/j.jhep.2021.04.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。